Beverly Hills Cancer Center

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas, Igor Puzanov, Reinhard Dummer et al. · The Lancet Oncology · 2015 · 1.5K citations · Full text

Medicine, Melanoma, Immunology +10

Cephalometrics for you and me

Cecil C. Steiner · American Journal of Orthodontics · 1953 · 1.3K citations

Neurophilosophy, Classics, Anatomy +1

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Grant A. McArthur, Paul B. Chapman, Caroline Robert et al. · The Lancet Oncology · 2014 · 969 citations · Full text

Medicine, Melanoma, Immunology +9

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Alexander M. Lesokhin, Michael H. Tomasson, Bertrand Arnulf et al. · Nature Medicine · 2023 · 483 citations · Full text

Hematological Malignancy, Magnetismm-3 Trial Results, Medicine +13

Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Jyoti D. Patel, Lada Krilov, Sylvia Adams et al. · Journal of Clinical Oncology · 2013 · 434 citations · Full text